Tranquis Therapeutics, Inc.
image1

 Discovering and developing novel immuno-therapeutics for neurological diseases

About Us

Engleman Laboratory

image2


Tranquis is an early-stage biotechnology company founded on cutting-edge neuro-immunology research from the laboratory of Prof. Edgar G. Engleman at Stanford University, which shows that altered metabolism of myeloid immune cells underlies a variety of central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, and age-related neuropathology.

Our insights and expertise

image3

Driven by fellow co-founder, Dr. Khoa D. Nguyen, the laboratory has made major advances in the field by engineering a unique R&D platform to identify abnormal immuno-neurological pathways via gene expression data in diseased humans and subsequently validate them in proprietary animal models.

In several models of CNS diseases, the company's lead compound potently suppresses abnormal activity of myeloid immune cells, resulting marked reduction in neuropathology as well as an extension of lifespan.

A groundbreaking biotech company

image4

Tranquis is being built on a strong and proprietary underlying scientific rationale that neuropathology associated with multiple CNS disorders results from abnormal activation of myeloid immune cells. 

The company completed a seed financing round in 2017 led by SR One and appointed Dr. Sanjay K. Kakkar as President & CEO in October 2018.

Contact Us

Tranquis Therapeutics, Inc.

101 Jefferson Dr, Menlo Park, CA 94025, USA